Vantage with Palki Sharma | N18G Pfizer has halted development of its potential weight loss pill after a patient suffered ...

Pfizer will end development of weight-loss pill over fears about its impact to the liver - The drugmaker said the patient’s ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The announcement adds to a string of setbacks in Pfizer’s bid to win a slice of the booming market that Wall Street projects ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer’s decision is a setback for the company, which had been trying to win a share of the booming GLP-1 market dominated by blockbuster drugs Wegovy and Zepbound from rivals Novo Nordisk and ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

The pharmaceutical giant halted the creation of danuglipron, an oral GLP-1 drug that was hoped would work like Ozempic in pill-form. Dr Chris Boshoff, Pfizer's Chief Scientific Officer ...

Pfizer is part of a growing group of rivals aiming to differentiate from the market leaders with drugs formulated as daily pills. Danuglipron, which was discovered internally within Pfizer ...